首页
>
期刊首页
>
中医杂志(英文版)
>
2026年4期
>
Yigongsan decoction(异功散)ameliorates anemia of chronic disease by attenuating mothers against decapentaplegic homolog-signal transducer and activator of transcription 3 interaction to regulate iron homeostasis
Yigongsan decoction(异功散)ameliorates anemia of chronic disease by attenuating mothers against decapentaplegic homolog-signal transducer and activator of transcription 3 interaction to regulate iron homeostasis
摘要
OBJECTIVE:To investigate how Yigongsan(异功散)decoction(YGS)regulates iron metabolism in anemia of chronic disease(ACD)by modulating the hepcidin-ferroportin axis,with particular focus on crosstalk between the mothers against decapentaplegic homolog(SMAD)and signal transducer and activator of transcription 3(STAT3)signaling pathways.
METHODS:In vivo:a lipopolysaccharide(LPS)-induced ACD mouse model was treated with YGS(15.413 g·kg-1·d-1)for 7 d.Iron metabolism was evaluated by measuring serum and splenic iron levels,as well as hepcidin antimicrobial peptide(HAMP)and ferroportin(Fpn)mRNA expression(quantitative real-time polymerase chain reaction,qRT-PCR),and protein-protein interactions(co-immunoprecipitation,Co-IP).In vitro:HepG2 cells were stimulated with interleukin-6(IL-6)or activin B and treated with 10%YGS-medicated serum.Iron metabolism was evaluated by intracellular and extracellular iron.STAT3/SMAD pathway activity was assessed by siRNA knockdown,Western blotting of phosphorylated SMAD1/5/8(p-SMAD1/5/8)and phosphorylated STAT3(p-STAT3),and Co-IP.
RESULTS:LPS-treated mice,YGS significantly decreased splenic iron content(P<0.01)and increased serum iron levels(P<0.05).Hepatic HAMP mRNA was downregulated,while Fpn mRNA was upregulated.In HepG2 cells,YGS counteracted IL-6/activin B-induced dysregulation,reducing hepcidin and intracellular iron while increasing ferroportin and extracellular iron.siRNA experiments confirmed that YGS restored the hepcidin-ferroportin balance independently of direct SMAD or STAT3 inhibition.Co-IP and immunofluorescence revealed that YGS attenuated the competitive interaction between phosphorylated SMAD 1/5/8(p-SMAD 1/5/8)and phosphorylated STAT3(p-STAT3),reducing their nuclear co-localization and subsequent HAMP transcription.
CONCLUSION:Our results suggest that YGS may alleviate ACD by attenuating the interaction between the SMAD and STAT3 pathways,which appears to lead to reduced STAT3 phosphorylation and hepcidin expression,thereby re-establishing iron homeostasis.This identifies YGS as a potential therapeutic agent targeting inflammation-induced iron dysregulation.
年,卷(期):
2026, 46(4)
机标分类号:
R783.5
TP3
G623.310.2
在线出版日期:
2026年10月19日